Sabitlenmiş Tweet
StockMinds007
9.4K posts

StockMinds007 retweetledi
StockMinds007 retweetledi
StockMinds007 retweetledi
StockMinds007 retweetledi
StockMinds007 retweetledi

$KWM KWM Signs Exclusive Global Distribution Agreement with HYBE Covering BTS, SEVENTEEN, LE SSERAFIM, and More — Targeting Annual Revenue in Excess of $100 Million
stocktitan.net/news/KWM/kwm-s…
English
StockMinds007 retweetledi
StockMinds007 retweetledi

$ISPC
iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time
- Implements a direct shipping model that cuts human biospecimen transit times by ~70–85% and enables domestic deliveries in as little as 1–2 days.
The change reduces reliance on central hubs, lowers shipping handoffs and costs, and pairs with strengthened European and Eastern European supplier partnerships to improve access to rare specimens and consistency for international requests.
stocktitan.net/news/ISPC/i-sp…
English
StockMinds007 retweetledi
StockMinds007 retweetledi
StockMinds007 retweetledi
StockMinds007 retweetledi
StockMinds007 retweetledi
StockMinds007 retweetledi

🚀 $MODD +12.3% — Modular Medical Receives FDA 510(k) Clearance for Pivot Tubeless Insulin Patch Pump
━━━━━━━━━━━━━━━━━━━━
📰 Modular Medical announced that its Pivot tubeless insulin patch pump received FDA 510(k) clearance on April 9, 2026. This clearance allows for commercial sale in the United States, with initial customer shipments expected by the end of the second quarter of 2026. The Pivot pump is designed as a two-part, removable, tubeless device featuring a 3 mL detachable reservoir, disposable battery, and smartphone connectivity for bolus and monitoring. It targets adults with type 1 or type 2 diabetes who a
✅ Positives
• FDA 510(k) clearance was achieved, enabling commercial sale in the U.S.
• The Pivot pump features a removable 3 mL reservoir and disposable battery, enhancing convenience.
• Manufacturing validation is progressing, supporting initial production for approximately 6,000 users.
⚠️ Risks
• The success of market acceptance and consumer demand remains uncertain.
• The timeline for obtaining the CE Mark and international expansion is still pending.
• Risks include potential challenges in high-volume manufacturing and regulatory approvals.
🤖 AI Impact: 4/5 High
💲 $5.73 (+12.3%) | Vol: 245.9K | MCap: 12.1M | Float: 1.9M (x0.13)
📊 app.ticker.guru/article?id=943…
#stocks #FDA #smallcaps
English
StockMinds007 retweetledi
StockMinds007 retweetledi
StockMinds007 retweetledi

For almost a year after a brief armed conflict with Pakistan, India has been trying to portray its nuclear-armed neighbor as a sponsor of terrorism that shouldn’t be trusted by other governments bloomberg.com/news/articles/…
English
StockMinds007 retweetledi
StockMinds007 retweetledi











